Potential therapeutic strategies for MASH: from preclinical to clinical development
文献类型：期刊论文
| 作者 | Xie, Zhifu1; Li, Yufeng1; Cheng, Long1,2; Huang, Yidan1,2; Rao, Wanglin1,2,3; Shi, Honglu1; Li, Jingya1,2,3
|
| 刊名 | LIFE METABOLISM
 |
| 出版日期 | 2024-08-01 |
| 卷号 | 3期号:5页码:loae029 |
| 关键词 | steatosis inflammation fibrosis metabolic dysfunction-associated steatohepatitis pharmacotherapy |
| DOI | 10.1093/lifemeta/loae029 |
| 文献子类 | Review |
| 英文摘要 | Current treatment paradigms for metabolic dysfunction-associated steatohepatitis (MASH) are based primarily on dietary restrictions and the use of existing drugs, including anti-diabetic and anti-obesity medications. Given the limited number of approved drugs specifically for MASH, recent efforts have focused on promising strategies that specifically target hepatic lipid metabolism, inflammation, fibrosis, or a combination of these processes. In this review, we examined the pathophysiology underlying the development of MASH in relation to recent advances in effective MASH therapy. Particularly, we analyzed the effects of lipogenesis inhibitors, nuclear receptor agonists, glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists, fibroblast growth factor mimetics, and combinatorial therapeutic approaches. We summarize these targets along with their preclinical and clinical candidates with the ultimate goal of optimizing the therapeutic prospects for MASH. |
| WOS关键词 | FATTY LIVER-DISEASE ; FARNESOID-X-RECEPTOR ; GROWTH-FACTOR 21 ; COA CARBOXYLASE INHIBITION ; DE-NOVO LIPOGENESIS ; IMPROVES INSULIN SENSITIVITY ; NONALCOHOLIC STEATOHEPATITIS ; NUCLEAR RECEPTOR ; BILE-ACIDS ; DOUBLE-BLIND |
| WOS研究方向 | Endocrinology & Metabolism |
| 语种 | 英语 |
| WOS记录号 | WOS:001327488400003 |
| 出版者 | OXFORD UNIV PRESS |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/317013]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Li, Jingya |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 189 GuoShouJing Rd, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 3.Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou 310024, Zhejiang, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xie, Zhifu,Li, Yufeng,Cheng, Long,et al. Potential therapeutic strategies for MASH: from preclinical to clinical development[J]. LIFE METABOLISM,2024,3(5):loae029. |
| APA | Xie, Zhifu.,Li, Yufeng.,Cheng, Long.,Huang, Yidan.,Rao, Wanglin.,...&Li, Jingya.(2024).Potential therapeutic strategies for MASH: from preclinical to clinical development.LIFE METABOLISM,3(5),loae029. |
| MLA | Xie, Zhifu,et al."Potential therapeutic strategies for MASH: from preclinical to clinical development".LIFE METABOLISM 3.5(2024):loae029. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。